rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Kevin Tang

10% owner

Company insider

Files Form 4 as: 10% owner, Boundless Bio; 10% owner, Fulcrum Therapeutics; Chief Executive Officer, Aurinia Pharmaceuticals; 10% owner, Singular Genomics Systems; 10% owner, Tcr2 Therapeutics; Director and 10% owner, Jounce Therapeutics; Chief Financial Officer, La Jolla Pharmaceutical Co; Chief Executive Officer, Odonate Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
307
Buys
115
Sells
6
Bought
$144.3M
Sold
$889K
Companies
18
Companies where not an officer
16
First trade
3 Jan 2005
Last trade
20 Oct 2026
Last filed
20 Oct 2026

Companies traded

Where they are an officer
AUPH Aurinia PharmaceuticalsDirector, Officer, 10% owner · Biotechnology · last 2 Jun 202615 buys · 0 sells
Odonate TherapeuticsDirector, Officer, 10% owner · last 23 Dec 202015 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
BOLD Boundless Bio10% owner · Biotechnology · last 20 Oct 202621 buys · 1 sell
FULC Fulcrum Therapeutics10% owner · Biotechnology · last 17 Jul 20265 buys · 0 sells
Singular Genomics Systems10% owner · last 21 Feb 20250 buys · 0 sells
Tcr2 Therapeutics10% owner · last 12 May 20232 buys · 0 sells
Jounce TherapeuticsDirector, 10% owner · last 3 May 20230 buys · 0 sells
La Jolla Pharmaceutical CoDirector, 10% owner · last 22 Aug 202217 buys · 0 sells
HRTX Heron TherapeuticsDirector, 10% owner, Other · Biotechnology · last 7 Jan 20205 buys · 0 sells
Mirati Therapeutics10% owner · last 20 Sep 20130 buys · 2 sells
Ardea Biosciences, Inc./DEDirector, 10% owner · last 19 Jun 201214 buys · 0 sells
Penwest Pharmaceuticals Co10% owner · last 10 Mar 20094 buys · 0 sells
TrimerisDirector · last 15 Dec 20080 buys · 1 sell
Aradigm10% owner · last 13 Oct 20081 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
016Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
20 Oct 2026filed 20 Oct 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$521220 at $2.37filing
19 Oct 2026filed 20 Oct 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$30K12,790 at $2.34filing
19 Oct 2026filed 20 Oct 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$43K18,279 at $2.33filing
16 Oct 2026filed 20 Oct 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$277K118,185 at $2.34filing
26 Aug 2026filed 28 Aug 2026BOLD Boundless BioBiotechnologySEC FORM 4 Sold$54K18,300 at $2.97filing
21 Jul 2026filed 21 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$7,2592,975 at $2.44filing
21 Jul 2026filed 21 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$7,2592,975 at $2.44filing
20 Jul 2026filed 21 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$3,9601,623 at $2.44filing
20 Jul 2026filed 21 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$3,9601,623 at $2.44filing
17 Jul 2026filed 21 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$647265 at $2.44filing
17 Jul 2026filed 21 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$647265 at $2.44filing
17 Jul 2026filed 20 Jul 2026FULC Fulcrum TherapeuticsBiotechnologySEC FORM 4 Bought$179K50,945 at $3.52filing
17 Jul 2026filed 20 Jul 2026FULC Fulcrum TherapeuticsBiotechnologySEC FORM 4 Bought$179K50,945 at $3.52filing
16 Jul 2026filed 20 Jul 2026FULC Fulcrum TherapeuticsBiotechnologySEC FORM 4 Bought$415K116,671 at $3.56filing
16 Jul 2026filed 20 Jul 2026FULC Fulcrum TherapeuticsBiotechnologySEC FORM 4 Bought$415K116,671 at $3.56filing
16 Jul 2026filed 16 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$45K18,491 at $2.44filing
16 Jul 2026filed 16 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$45K18,491 at $2.44filing
15 Jul 2026filed 16 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$3,9041,600 at $2.44filing
15 Jul 2026filed 16 Jul 2026BOLD Boundless BioBiotechnologySEC FORM 4 Bought$3,9041,600 at $2.44filing
15 Jul 2026filed 15 Jul 2026FULC Fulcrum TherapeuticsBiotechnologySEC FORM 4 Bought$382K107,377 at $3.56filing

Sectors

Health Care50
Not placed71

Buys in green, sells in red, by the company’s sector.

Related people

Stephen P. RobertsonChief Legal Officer · Chief Legal Officer at Aurinia Pharmaceuticals, filing Form 4 there in the last year
Tina Susan NovaDirector · Director at Aurinia Pharmaceuticals, filing Form 4 there in the last year
Craig A. JohnsonDirector · Director at Aurinia Pharmaceuticals, filing Form 4 there in the last year
Jeffrey Allen BaileyDirector · Director at Aurinia Pharmaceuticals, filing Form 4 there in the last year
Kathleen GoetzDirector · Director at Aurinia Pharmaceuticals, filing Form 4 there in the last year